Surrozen filings document a biotechnology issuer focused on Wnt signaling and antibody technologies for ophthalmic disease. Recent Form 8-K reports disclose operating results, financial condition, pipeline business updates for SZN-8141 and related retinal disease programs, and collaboration and license revenue tied to research milestones.
The company's regulatory reports also record governance and compensation matters, including board and executive changes and inducement equity arrangements, along with material-agreement disclosures such as the termination of the TCGFB collaboration for antibody discovery services. Cover-page data and exhibits identify Surrozen common stock and redeemable warrants as part of the public-company capital structure.
Surrozen, Inc. (SRZN) reported insider buying by affiliated investment funds. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., both 10% holders, executed a series of open-market purchases of Common Stock on March 12–16, 2026, totaling 48,997 shares according to the filing’s transaction summary.
The trades were made at prices between 24.8769 and 24.9857 per share and are reported as indirect holdings. TCG Crossover GP II, LLC and TCG Crossover GP III, LLC act as general partners to the funds, and Chen Yu may be deemed to share voting, investment and dispositive power over these securities.
Surrozen, Inc. executive Li Yang received new equity awards consisting of stock options and restricted stock units. On February 17, 2026, Yang was granted options to purchase 100,950 shares of common stock at an exercise price of $0.00 per share and 100,950 restricted stock units.
The stock options vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. The RSUs vest in four equal annual installments beginning February 1, 2026, also subject to continued service. These awards represent direct ownership incentives rather than open-market share purchases.
Williams Charles O reported acquisition or exercise transactions in this Form 4 filing.
Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received two new equity awards. On February 17, 2026, he was granted employee stock options covering 102,900 shares of common stock at a grant price of $0.00 per share. These option shares vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. He was also granted 102,900 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning February 1, 2026, also subject to continued service.
Surrozen, Inc. reported that Chief Executive Officer Craig C. Parker received new equity awards. On February 17, 2026, he was granted an employee stock option covering 242,200 shares of common stock at an exercise price of $0.0000 per share, held as direct ownership.
The option vests over four years in 48 equal monthly installments starting from February 1, 2026, conditioned on continued service. Parker was also granted 242,200 restricted stock units, each representing one share of common stock. These RSUs vest in four equal annual installments beginning on February 1, 2026, also subject to continued service.
Braidwell and affiliates disclosed a significant position in Surrozen, Inc. common stock. As of December 31, 2025, Braidwell LP, Braidwell Management LLC, Alexander T. Karnal, and Brian J. Kreiter may be deemed beneficial owners of 470,000 shares, representing about 5.5% of Surrozen’s outstanding common stock.
All 470,000 shares are directly owned by Braidwell Partners Master Fund LP, with each reporting person sharing voting and dispositive power and no sole authority. The stake is reported as being held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Surrozen, Inc. received an updated ownership report showing that RA Capital Management, its affiliated fund, and principals Peter Kolchinsky and Rajeev Shah collectively report beneficial ownership of 871,731 shares of common stock, representing 9.2% of the class as of December 31, 2025.
The position includes Series A warrants for up to 322,580 shares, Series B warrants for up to 350,876 shares, and Series E warrants for up to 198,275 shares of common stock. The filing states the securities are not held for the purpose of changing or influencing control of Surrozen.
StemPoint Capital and related parties reported a significant ownership stake in Surrozen, Inc. The Schedule 13G/A shows StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross collectively beneficially owning 619,766 shares of Surrozen common stock, including 329,658 shares issuable upon exercise of warrants.
This represents 7.0% of Surrozen’s common stock, calculated using 8,571,421 shares outstanding as of November 5, 2025, plus specified Series A, B, and E warrants subject to a 9.9% beneficial ownership limitation. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico filed an amended Schedule 13G reporting beneficial ownership of 316,289 shares of Surrozen, Inc. common stock, representing 3.6% of the class as of the reported date.
The stake consists of 113,631 shares of common stock plus 202,658 shares issuable upon exercise of Series A, Series B and Series E warrants, all subject to a 9.9% beneficial ownership limitation. The percentage is based on 8,571,421 shares outstanding as of November 5, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control.
TCG Crossover investment entities increased their indirect stake in Surrozen, Inc. common stock through open-market purchases. On February 11, 2026, TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. each bought 8,882 and 8,881 shares at $23.575 per share, respectively. On February 12, 2026, they bought additional blocks of 547 and 546 shares at $23.8625 per share. After these transactions, one fund reported beneficial ownership of 651,114 shares and the other 651,112 shares, all held indirectly through the TCG Crossover fund structure.
Surrozen, Inc. (SRZN) received an amended Schedule 13G from several Millennium-related investment entities reporting significant passive ownership of its common stock as of 12/31/2025. Integrated Core Strategies (US) LLC reports beneficial ownership of 718,724 shares, representing 8.4% of the outstanding common stock.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 726,193 shares, or 8.5% of the class, with shared voting and dispositive power and no sole voting or dispositive power. The filing states these securities are held through entities over which Millennium Management LLC and related managers exercise voting control and investment discretion.
The reporting persons certify the securities were not acquired and are not held for the purpose of changing or influencing control of Surrozen, and the filing is made under the passive ownership framework of Schedule 13G.